drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, non-engineered, ex vivo–expanded polyclonal TIL therapy that recognizes tumor antigens via native TCRs and mediates cytotoxicity (perforin/granzyme, cytokines); administered IV at 9×10^10 cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, non-engineered, ex vivo–expanded polyclonal TILs that recognize tumor antigens via native TCR–MHC interactions and kill tumor cells through perforin/granzyme release and cytokine-mediated cytotoxicity after IV infusion.
drug_name
BST08 (tumor-infiltrating lymphocytes, TILs)
nct_id_drug_ref
NCT06643910